Rani Therapeutics Holdings, Inc. announced the successful oral delivery of a monoclonal antibody, Humira (adalimumab), via its high-capacity capsule, the RaniPill® HC, in a preclinical study. Data Highlights: Rani conducted a preclinical study tracking the serum concentrations of adalimumab, following the oral administration of the enteric-coated, RaniPill®HC capsule containing 11mg of Humira®? (adalimumab) to four canine models.

The RaniPill® CO successfully delivered adalimumab in all of the subjects. All device remnants were excreted normally without sequelae. Rani has orally administered the RaniPill®® HC in multiple preclinical studies, including with teriparatide and adalimumab, and has achieved a greater than 90% drug delivery success rate across such studies.